Generic selectors
Exact matches only
Search in title
Search in content
Filter by Categories
Deals
Features
News
Region
Sectors
Size

$40m-$99.9m

HawkEye 360 hooks $55m in series C
Esri helped Allied Minds' satellite constellation operator take its total funding to $155m in a round that will fund the launch of more satellites.
Metagenomi magnifies series A to $75m
UC Berkeley's DNA-editing technology spinout has raised $10m from RA Capital in addition to the $65m it pocketed in November.
JGC invests $40m in NuScale Power
JGC Holdings bacame the latest investor in the modular nuclear reactor technology developer, which emerged out of Oregon State University.
Immune-Onc gets $73m funding influx
The cancer therapy developer, which is commercialising research from University of Texas, has raised series B1 and B2 financing.
OncoResponse raises $40.6m series C
MD Anderson Cancer Center spinout OncoResponse has added $40.6m to its coffers thanks to series C investors including Arch Venture Partners.
Fortis fortifies with $40m
Existing backers Lilly Asia Ventures and Osage University Partners helped the UCSF cancer therapy spinout close its series A round.
Asher Bio assesses $55m series A
Asher Bio has launched with $55m in series A financing to commercialise research partially conducted at WashU and Leiden.
PhoreMost advances with $46m series B
Parkwalk Advisors has returned to back a $46m round for PhoreMost, weeks after the latter’s spinout Neophore attracted $21m in a series B.

Other News

Meatable meets investors for $47m series A
The lab-grown meat developer has picked up $47m in its series A round thanks to commitments from investors including Section 32 and Agronomics.
Innoforce impresses with $96m series A
Peking University-backed Yanchuang Capital co-led a series A round for Innoforce Pharmaceuticals that will support the construction of manufacturing facilities.
ZGBiotech zooms in on series B
Cash Capital has participated in a $70m series B round for Shanghai ZhenGe Biotechnology, bringing the company’s total financing to $125m.
Amphista ties up $53m series B
Forbion and Gilde Healthcare have co-led a $53m series B round for Dundee spinout Amphista, which is working on targeted protein degradation technology.
StrideBio strikes $81.5m series B deal
UF Innovate Ventures has contributed to a series B round for StrideBio, partially based on research into gene therapies at University of Florida.
Monte Rosa scales $95m series C
The money will fund the progress of the University of London-linked precision medicine developer's lead drug candidate into the clinic.

Editor's Picks

Big deal: Oxford PV begins capturing series D
Goldwind, Legal & General and Equinor have all taken part in a series D that achieved a $41m first close and boosted the Oxford spinout’s total equity and debt to more than $118m.
Big deal: Ribon ties together $65m series B
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Big deal: NMD flexes series A muscles
Aarhus University spinout NMD Pharma, which focuses on therapies for neuromuscular conditions, has attracted the support of several corporates for its $47m series A round.
Big deal: Touchstone helps inject $73m into Cell Medica
Touchstone Innovations, which co-founded the cellular immunotherapy developer in 2007, has contributed to another funding round.
test reg

Login